January 20, 2011 – Researchers say radiofrequency fields can successfully treat pancreatic tumors, which kill more than 95 percent of diagnosed patients. Kanzius Cancer Research Foundation (KCRF) announced research conducted in the Kanzius/Curley Lab at The University of Texas M.D. Anderson Cancer Center was published in the December 2010 issue of the American Association of Cancer Research's Clinical Cancer Research journal.

Studies found that noninvasive radiofrequency (RF) fields were effective in controlling relatively large malignant pancreatic tumors. Additionally, this process took place without any injury to surrounding tissue or changes in non-human subject behavior. The manuscript illustrates how doctors Steven A. Curley and Evan S. Glazer's studies prove that radiofrequency fields can treat pancreatic tumors
The manuscript describes the process as non-human subjects are exposed to 10 minutes of nonionizing RF radiation followed by 36 hours of treatment using targeted gold nanoparticles (AuNP). This data shows the Kanzius RF machine alongside these particular nanoparticles create an effective formula for controlling pancreatic cancer cells.

"John Kanzius, who created the RF device, once envisioned a cancer treatment that would be both effective and have zero side effects," said Curley, chief of gastrointestinal tumor surgery and program director of multidisciplinary gastrointestinal cancer care at the University of Texas M. D. Anderson Cancer Center. "These experiments demonstrate that the Kanzius RF device controls pancreatic cancer cells without any damage to nearby cells, or normal tissues and organs. We still have a lot of work to do but this is an important proof of principle."

"Every day, our team at the Kanzius Cancer Research Foundation works to help fund this incredible research," said Mark Neidig, executive director of KCRF. "These recent findings bring us one step closer to producing an effective, noninvasive cancer treatment that doesn't have the side effects associated with current treatments like chemotherapy and radiation."

This manuscript "Noninvasive Radiofrequency Field Destruction of Pancreatic Andenocarcinoma Xenografts Treated with Targeted Gold Nanoparticles" can be found at http://www.kanziuscancerresearch.org/research/published_research_manusc….

For more information: www.Kanzius.org


Related Content

News | Radiopharmaceuticals and Tracers

Jan. 29, 2026 — The American Society for Radiation Oncology (ASTRO) has launched a national program creating Authorized ...

Time January 30, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Radiology Imaging

Jan. 21, 2026 — Cathpax, a spin-off of the Lemer Pax group that designs, develops and commercializes team-wide, full ...

Time January 22, 2026
arrow
News | Radiation Therapy

Jan. 16, 2026 — Elekta has announced that its Elekta Evo* CT-Linac has received 510(k) clearance from the U.S. Food and ...

Time January 16, 2026
arrow
News | Radiopharmaceuticals and Tracers

Dec. 11, 2025 — Telix Pharmaceuticals Ltd. has announced a strategic clinical collaboration with Varian, a Siemens ...

Time December 11, 2025
arrow
News | FDA

Dec. 02, 2025 — Alpha Tau Medical Ltd., the developer of the alpha-radiation cancer therapy Alpha DaRT, has announced ...

Time December 04, 2025
arrow
News | Interventional Radiology

Nov. 12, 2025 — On Nov. 11, Huntsman Cancer Institute at the University of Utah (the U) opened its first specialized ...

Time November 13, 2025
arrow
News | Radiology Business

Nov. 12, 2025 — Siemens has announced plans to deconsolidate its remaining stake in Siemens Healthineers (currently ...

Time November 13, 2025
arrow
News | Radiopharmaceuticals and Tracers

Nov. 11, 2025 — The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has released a position paper outlining ...

Time November 12, 2025
arrow
News | Prostate Cancer

Nov. 10, 2025 — Researchers at Wayne State University and the Barbara Ann Karmanos Cancer Institute have developed a ...

Time November 11, 2025
arrow
Subscribe Now